🇺🇸 FDA
Patent

US 8957070

Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity

granted A61PA61P3/04A61P3/10

Quick answer

US patent 8957070 (Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity) held by Takeda Pharmaceutical Company Limited expires Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Feb 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P3/04, A61P3/10, A61P43/00